S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69

Adial Pharmaceuticals Stock Forecast, Price & News

-0.15 (-6.02%)
(As of 01/21/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
211,052 shs
Average Volume
129,139 shs
Market Capitalization
$48.59 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Adial Pharmaceuticals logo

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the treatment of alcohol use disorder. Its lead product is AD04, a selective serotonin-3 antagonist. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.28 per share


Net Income
$-10.89 million
Pretax Margin




Free Float
Market Cap
$48.59 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.26 out of 5 stars

Medical Sector

328th out of 1,418 stocks

Pharmaceutical Preparations Industry

150th out of 684 stocks

Analyst Opinion: 3.5Community Rank: 3.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

Is Adial Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adial Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Adial Pharmaceuticals stock.
View analyst ratings for Adial Pharmaceuticals
or view top-rated stocks.

How has Adial Pharmaceuticals' stock been impacted by COVID-19?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ADIL stock has increased by 73.3% and is now trading at $2.34.
View which stocks have been most impacted by COVID-19

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 28th 2022.
View our earnings forecast for Adial Pharmaceuticals

How were Adial Pharmaceuticals' earnings last quarter?

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.22).
View Adial Pharmaceuticals' earnings history

What price target have analysts set for ADIL?

4 equities research analysts have issued twelve-month price targets for Adial Pharmaceuticals' shares. Their forecasts range from $5.00 to $15.00. On average, they expect Adial Pharmaceuticals' share price to reach $11.00 in the next year. This suggests a possible upside of 370.1% from the stock's current price.
View analysts' price targets for Adial Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:
  • William B. Stilley, President, Chief Executive Officer & Director
  • Cary J. Claiborne, Chief Operating Officer & Director
  • Joseph Truluck, Chief Financial Officer, Secretary & Treasurer
  • Bankole A. Johnson, Chief Medical Officer (LinkedIn Profile)
  • Julien Dimastromatteo, Vice President-Business Operations & Research

What other stocks do shareholders of Adial Pharmaceuticals own?

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.34.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals has a market capitalization of $48.59 million. The company earns $-10.89 million in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Adial Pharmaceuticals have?

Adial Pharmaceuticals employs 2,018 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is www.adialpharma.com.

Where are Adial Pharmaceuticals' headquarters?

Adial Pharmaceuticals is headquartered at 1180 Seminole Trail Suite 495, Charlottesville VA, 22901.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at (434) 422-9800 or via email at [email protected].

This page was last updated on 1/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.